Experience in correcting eating disorders in the clinic of mental illness





Metoclopramide, Ondansetron, mental illness, Eating disorders


Introduction: Eating disorders - a class of psychogenic behavioral syndromes associated with eating disorders. The class of these disorders includes anorexia nervosa, bulimia nervosa, compulsive overeating, as well as several other disorders, which are included in the international classification, to section F 50-F 59.

Purpose: The purpose of our study is to trace the dynamics of individual eating disorders in patients with various mental illnesses under the influence of corrective therapy.

Methodology: Were examined 77 patients with various mental diseases who have had eating disorders. The first (I) group included 33 patients. They have added Metoclopramide at a dose of 20 mg/day to the main treatment. The second group (II) - 44 patients who received the drug Ondansetron at a dose of 4 mg/day, respectively. The condition of all patients was assessed according to the following scales: Eating Attitudes Test (EAT-26), 36-Item Short-Form Health Status (SF-36). Body mass index (BMI) was calculated to study the dynamics of weight. All examinations of patients were performed at the beginning and after 14 days of treatment.

Results: According to the EAT-26 scale the average score in the I group was 29 ± 2.8 points, and in the II - 30.1 ± 2.4, respectively. According to the SF-36 questionnaire, the average total score in the I group was - 69.5 ± 1.8 before treatment, 79.5 ± 1.6 - after treatment improved by 12.5% (p <0,05). In group II - 70.8 ± 1.2 and 89.4 ± 1.5, improving by 20.8%, respectively (p <0.05). Under the influence of the therapy, the patients' manifestations of eating behavior decreased, which contributed to the growth of BMI: in group I - by 2.1 ± 1.3 kg, in group II - by 3.5 ± 2.3 kg, which is 1.6 times more.

Conclusions: The drug Ondansetron, intended for the correction of eating disorders, in combination with therapy of the underlying pathology, was likely to be more effective than Metoclopramide hydrochloride, which should be considered in practical psychiatry


Galmiche, M., Déchelotte, P., Lambert, G., & Tavolacci, M. P.. (2019). Prevalence of eating disorders over the 2000–2018 period: a systematic literature review. The American Journal of Clinical Nutrition, 109(5), 1402–1413. https://doi.org/10.1093/ajcn/nqy342 DOI: https://doi.org/10.1093/ajcn/nqy342

Ilnytska Tetyana (2018). Eating Disorders: Myths and Facts [??????????? ??????]. NeuroNews. ? 4-5 (97). [Electronic resource]. – Access mode: URL:https://neuronews.com.ua/ua/archive/2018/4-5%2897%29/pages-6-7/rozladi-harchovoyi-povedinki-mifi-ta-fakti#gsc.tab=0

Schaumberg, K., Welch, E., Breithaupt, L., Hübel, C., Baker, J. H., Munn-Chernoff, M. A., Yilmaz, Z., Ehrlich, S., Mustelin, L., Ghaderi, A., Hardaway, A. J., Bulik-Sullivan, E. C., Hedman, A. M., Jangmo, A., Nilsson, I. A. K., Wiklund, C., Yao, S., Seidel, M., & Bulik, C. M.. (2017). The Science Behind the Academy for Eating Disorders' Nine Truths About Eating Disorders. European Eating Disorders Review, 25(6), 432–450. https://doi.org/10.1002/erv.2553 DOI: https://doi.org/10.1002/erv.2553

Streatfeild, J., Hickson, J., Austin, S. B., Hutcheson, R., Kandel, J. S., Lampert, J. G., Myers, E. M., Richmond, T. K., Samnaliev, M., Velasquez, K., Weissman, R. S., & Pezzullo, L. (2021). Social and economic cost of eating disorders in the United States: Evidence to inform policy action. The International journal of eating disorders, 54(5), 851–868. https://doi.org/10.1002/eat.23486 DOI: https://doi.org/10.1002/eat.23486




How to Cite

Romash, I., Romash, I., Kukhta, O., Dzivak, K., & Ahmed, H. . (2021). Experience in correcting eating disorders in the clinic of mental illness. Mental Health: Global Challenges Journal, 4(2). https://doi.org/10.32437/mhgcj.v4i2.127

Most read articles by the same author(s)